Precigen, Inc. (PGEN) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

We'll be right back. Thank you. Thank you. music music Thank you. We'll be right back. Thank you. Good afternoon, ladies and gentlemen, and welcome to the President's First Quarter 2026 Financial Results and Business Updates Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, May 13, 2026. And I would now like to turn the conference over to Mr. Steven Karasim. Please go ahead, sir. Thank you, operator, and thank you for all those joining us today for our Q1 2026 update call. Joining me today are Dr. Helen Sabzabari, our president and CEO, Phil Tennant, our chief commercial officer, Harry Tomasi, our CFO, and Ritul Shah, our COO. Before we begin our prepared remarks, I remind everyone that we will be making certain forward-looking statements during this call. These statements are based on our current expectations and beliefs. We encourage you to review the slide in this presentation, as well as our SEC filings, which include risks and uncertainties that could cause actual results to differ materially from today's forward-looking statements. With that, I will now turn the call over to Dr. Sabzabari. Thank you, Steve, and thank you to all those joining us for our Q1 update call. The approval of Paximius in August of 2025 has brought a novel first-line standard of care treatment for adults with RRP. In nine short months, we have witnessed tremendous progress with the first commercial therapeutic launch in the disease's history. Since last reporting in March, the launch has continued to show accelerating momentum. The early success and tr...